New hope for advanced prostate cancer: drug cocktails enter human trials

NCT ID NCT07230106

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II study tests two experimental drugs, HS-20093 and SHR2554, combined with standard hormone therapies in 218 men with metastatic prostate cancer. The goal is to see if these combos are safe and can lower PSA levels or slow the cancer's spread. Participants must have adenocarcinoma and be in good overall health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HS-20093, SHR2554, abiraterone, enzalutamide, darotamine
What this could lead to: If successful, this could lead to new combination treatments that better control metastatic prostate cancer and delay disease progression.
What could go wrong: This is an early phase II trial with a small number of participants, so results may not apply to all patients. The combinations may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Nanjing Drum Tower Hospital
RECRUITING

Nanjing, Jiangsu, 210009, China
Tianjin Medical University Cancer Institute and Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.